

Labordiagnostische Studie zur individuellen Stimulation der natürlichen Killerzellen (NK-Zellen) durch Vitalpilze

PD Dr. rer. nat. et med. habil. Stephan Sudowe
Erich-Dombrowski-Straße 3
55127 Mainz | Deutschland
dr.sudowe@ganzimmun.de
www.ganzimmun.de

Literatur

- [1] Lanier LL, et al. 1986. Natural killer cells: definition of a cell type rather than a function. *J Immunol*; 137(9): 2735–9.
- [2] Morvan MG, Lanier LL. 2016. NK cells and cancer: you can teach innate cells new tricks. *Nat Rev Cancer*; 16(1): 7–19.
- [3] Wu Y, et al. 2025. MHC-I pathway disruption by viruses: insights into immune evasion and vaccine design for animals. *Front Immunol*; 16: 1540159.
- [4] Cornel AM, et al. 2020. MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. *Cancers*; 12(7): 1760.
- [5] Prager I, Watzl C. 2019. Mechanisms of natural killer cell-mediated cellular cytotoxicity. *J Leukoc Biol*; 105(6): 1319–29.
- [6] Langers I, et al. 2012. Natural killer cells: role in local tumor growth and metastasis. *Biologics*; 6: 73–82.
- [7] López-Soto A, et al. 2017. Control of metastasis by NK cells. *Cancer Cell*; 32(2): 135–54.
- [8] González FM, et al. 1998. Prognostic significance of natural killer cell activity in patients with laryngeal carcinoma. *Arch Otolaryngol Head Neck Surg*; 124(8): 852–6.
- [9] Taketomi A, et al. 1998. Natural killer cell activity in patients with hepatocellular carcinoma. A new prognostic indicator after hepatectomy. *Cancer*; 83(1): 58–63.
- [10] Imai K, et al. 2000. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. *Lancet*; 356(9244): 1795–9.
- [11] Mirjagic Martinovic K, et al. 2011. The stage dependent changes in NK cell activity and the expression of activating and inhibitory NK cell receptors in melanoma patients. *J Surg Res*; 171(2): 637–49.
- [12] Jobin G, et al. 2017. Association between natural killer cell activity and colorectal cancer in high-risk subjects undergoing colonoscopy. *Gastroenterology*; 153(4): 980–7.
- [13] Hansen TF, et al. 2019. Correlation between natural killer cell activity and treatment effect in patients with disseminated cancer. *Transl Oncol*; 12(7): 968–72.
- [14] Eguizabal C, et al. 2020. Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing. *Stem Cell Res Ther*; 11(1): 453.
- [15] Deng X, et al. 2021. Immunosurveillance of cancer and viral infections with regard to alterations of human NK cells originating from lifestyle and aging. *Biomedicine*; 9(5): 557.
- [16] Brauning A, et al. 2022. Aging of the immune system: focus on natural killer cells phenotype and functions. *Cells*; 11(6): 1017.
- [17] Costello RT, et al. 2002. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. *Blood*; 99(10): 3661–7.
- [18] Hoffmann C, et al. 2025. Cancer cells suppress NK cell activity by actin-driven polarization of inhibitory ligands to the immunological synapse. *Proc Natl Acad Sci USA*; 122(32): e2503259122.
- [19] Szkaradkiewicz A, et al. 2010. Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF- β 1) in patients with gastric cancer. *J Biomed Biotechnol*; 2010: 901564.
- [20] Peng LS, et al. 2017. Tumor-associated monocytes/macrophages impair NK-cell function via TGF β 1 in human gastric cancer. *Cancer Immunol Res*; 5(3): 248–56.
- [21] Ma Y, et al. 2016. Viral evasion of natural killer cell activation. *Viruses*; 8(4): 95.
- [22] Mancini M, Vidal SM. 2020. Mechanisms of natural killer cell evasion through viral adaptation. *Annu Rev Immunol*; 38: 511–39.
- [23] Stricker RB, Winger EA. 2001. Decreased CD57 lymphocyte subset in patients with chronic Lyme disease. *Immunol Lett*; 76(1): 43–8.
- [24] Savchenko AA, et al. 2023. Recombinant human interleukin-2 corrects NK cell phenotype and functional activity in patients with post-COVID syndrome. *Pharmaceuticals*; 16(4): 537.
- [25] Baraniuk JN, et al. 2024. Meta-analysis of natural killer cell cytotoxicity in myalgic encephalomyelitis/chronic fatigue syndrome. *Front Immunol*; 15: 1440643.
- [26] Katz AR, et al. 2025. Impact of psychological stressors on natural killer cell function: a comprehensive analysis based on stressor type, duration, intensity, and species. *Physiol Behav*; 288: 114734.
- [27] Saurabh A, et al. 2026. The interplay between loneliness, cortisol, and NK cell function: The role of cortisol in NK cell dysfunction. *Psychoneuroendocrinology*; 189: 107870.

- [28] Tobin LM, et al. 2017. NK cells in childhood obesity are activated, metabolically stressed, and functionally deficient. *JCI Insight*; 2(24): e94939.
- [29] O'Shea D, Hogan AE. 2019. Dysregulation of natural killer cells in obesity. *Cancers*; 11(4): 573.
- [30] Jung YS, et al. 2018. Physical inactivity and unhealthy metabolic status are associated with decreased natural killer cell activity. *Yonsei Med J*; 59(4): 554–62.
- [31] Fondell E, et al. 2011. Short natural sleep is associated with higher T cell and lower NK cell activities. *Brain Behav Immun*; 25(7): 1367–75.
- [32] De Lorenzo BH, et al. 2015. Sleep-deprivation reduces NK cell number and function mediated by β -adrenergic signaling. *Psychoneuroendocrinology*; 57: 134–43.
- [33] Ochshorn-Adelson M, et al. 1994. Effects of ethanol on human natural killer cell activity: in vitro and acute, low-dose in vivo studies. *Alcohol Clin Exp Res*; 18(6): 1361–7.
- [34] Ben-Eliyahu S, et al. 1996. Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis. *Nat Med*; 2(4): 457–60.
- [35] Firoz Mian M, et al. 2008. Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. *J Leukoc Biol*; 83(3): 774–84.
- [36] Jung YS, et al. 2020. Impact of smoking on human natural killer cell activity: a large cohort study. *J Cancer Prev*; 25(1): 13–20.
- [37] Wang D, et al. 2024. Natural killer cells in cancer immunotherapy. *MedComm* (2020); 5(7): e626.
- [38] Wu Y, et al. 2025. Enhancing NK cell antitumor activity with natural compounds: research advances and molecular mechanisms. *Phytother Res*; 39(5): 1905–29.
- [39] Grudzien M, Rapak A. 2018. Effect of natural compounds on NK Cell activation. *J Immunol Res*; 2018: 4868417.
- [40] Braedel-Ruoff S. 2010. Immunomodulatory effects of *Viscum album* extracts on natural killer cells: review of clinical trials. *Forsch Komplementmed*; 17(2): 63–73.
- [41] Guggenheim AG, et al. 2014. Immune modulation from five major mushrooms: application to integrative oncology. *Integr Med (Encinitas)*; 13(1): 32–44.
- [42] Filippini T, et al. 2023. Selenium and immune function: a systematic review and meta-analysis of experimental human studies. *Am J Clin Nutr*; 117(1): 93–110.
- [43] Amling L, et al. 2025. Short-term oral zinc supplementation enhances natural killer cell functionality and decreases circulating innate lymphoid cell counts and frequencies in healthy young adults. *J Transl Med*; 23: 333.
- [44] Hamdan TA. 2025. Impact of micronutrients and macronutrients on NK cells immunity. *Cell Physiol Biochem*; 59(3): 313–29.
- [45] Whiteside TL. 2001. Measurement of cytotoxic activity of NK/LAK cells. *Curr Protoc Immunol*; Chapter 7: Unit 7.18.
- [46] Cholujoová D, et al. 2008. Comparative study of four fluorescent probes for evaluation of natural killer cell cytotoxicity assays. *Immunobiology*; 213(8): 629–40.
- [47] Lötzerich H, Wirt H. 1997. Durchflusszytometrische nichtradioaktive Methode zur Bestimmung der zytotoxischen Aktivität von natürlichen Killerzellen: Vergleich mit dem klassischen ^{51}Cr -Release-Assay. *J Lab Med*; 21(1): 13–20.
- [48] Dons'koi BV, et al. 2011. Measurement of NK activity in whole blood by the CD69 up-regulation after co-incubation with K562, comparison with NK cytotoxicity assays and CD107a degranulation assay. *J Immunol Methods*; 372(1–2): 187–95.
- [49] Nagel JE, et al. 1981. Spontaneous or natural killer cytotoxicity of K562 erythroleukemic cells in normal patients. *Cancer Res*; 41(6): 2284–8.
- [50] Lozzio CB, Lozzio BB. 1975. Human chronic myelogenous leukemia cell-like with positive philadelphia chromosome. *Blood*; 45(3): 321–34.
- [51] Lozzio BB, Lozzio CB. 1979. Properties and usefulness of the original K-562 human myelogenous leukemia cell line. *Leuk Res*; 3(6): 363–70.
- [52] Pamies D, et al. 2022. Guidance document on Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0). *ALTEX*; 39(1): 30–70.
- [53] Kabelitz D, et al. 1985. Recombinant interleukin 2 rapidly augments human natural killer cell activity. *Cell Immunol*; 93(1): 38–45.
- [54] Sudowe S, Sonntag D. 2021. Effects of *Bacillus firmus* e volumine ex muris cellulae 6x on cytolytic activity of natural killer cells in vitro. *Int J High Dil Res*; 20(2–3): 34–43.
- [55] Venturella G, et al. 2021. Medicinal mushrooms: bioactive compounds, use, and clinical trials. *Int J Mol Sci*; 22(2): 634.
- [56] Jeitler M, et al. 2020. Significance of medicinal mushrooms in integrative oncology: a narrative review. *Front Pharmacol*; 11: 580656.
- [57] Zade S, et al. 2025. Mushroom-derived bioactive compounds pharmacological properties and cancer targeting: a holistic assessment. *Discov Oncol*; 16(1): 654.
- [58] Kirdeeva Y, et al. 2026. The inclusion of dietary and medicinal mushrooms into translational oncology: pros and cons at the molecular level. *Int J Mol Sci*; 27(3): 1312.
- [59] Fujimiya Y, et al. 1998. Selective tumoricidal effect of soluble proteoglycan extracted from the basidiomycete, *Agaricus blazei* Murill, mediated via natural killer cell activation and apoptosis. *Cancer Immunol Immunother*; 46(3): 147–59.
- [60] Ahn WS, et al. 2004. Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, *Agaricus blazei* Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. *Int J Gynecol Cancer*; 14(4): 589–94.
- [61] Kaneno R, et al. 2004. Effects of extracts from Brazilian sun-mushroom (*Agaricus blazei*) on the NK activity and lymphoproliferative responsiveness of Ehrlich tumor-bearing mice. *Food Chem Toxicol*; 42(6): 909–16.
- [62] Niu YC, et al. 2009. Immunostimulatory activities of a low molecular weight antitumoral polysaccharide isolated from *Agaricus blazei* Murill (LMPAB) in Sarcoma 180 ascitic tumor-bearing mice. *Pharmazie*; 64(7): 472–6.

- [63] Tang NY, et al. 2009. Effects of *Agaricus blazei* Murill extract on immune responses in normal BALB/c mice. *In vivo*; 23(5): 761–6.
- [64] Lin JG, et al. 2012. An extract of *Agaricus blazei* Murill administered orally promotes immune responses in murine leukemia BALB/c mice *in vivo*. *Integr Cancer Ther*; 11(1): 29–36.
- [65] Lu CC, et al. 2016. Immunomodulatory properties of medicinal mushrooms: differential effects of water and ethanol extracts on NK cell-mediated cytotoxicity. *Innate Immun*; 22(7): 522–33.
- [66] Lu H, et al. 2011. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. *Clin Cancer Res*; 17(21): 6742–53.
- [67] Torkelson CJ, et al. 2012. Phase 1 clinical trial of *Trametes versicolor* in women with breast cancer. *ISRN Oncol*; 2012: 251632.
- [68] Benson KF, et al. 2019. The mycelium of the *Trametes versicolor* (Turkey tail) mushroom and its fermented substrate each show potent and complementary immune activating properties *in vitro*. *BMC Complement Altern Med*; 19(1): 342.
- [69] Yim MH, et al. 2007. Soluble components of *Hericium erinaceum* induce NK cell activation via production of interleukin-12 in mice splenocytes. *Acta Pharmacol Sin*; 28(6): 901–7.
- [70] Wu F, Huang H. 2021. Surface morphology and protective effect of *Hericium erinaceus* polysaccharide on cyclophosphamide-induced immunosuppression in mice. *Carbohydr Polym*; 251: 116930.
- [71] Kodama N, et al. 2003. Effect of maitake (*Grifola frondosa*) D-Fraction on the activation of NK cells in cancer patients. *J Med Food*; 6(4): 371–7.
- [72] Kodama N, et al. 2005. Enhancement of cytotoxicity of NK cells by D-Fraction, a polysaccharide from *Grifola frondosa*. *Oncol Rep*; 13(3): 497–502.
- [73] Vetvicka V, Vetvickova J. 2014. Immune-enhancing effects of Maitake (*Grifola frondosa*) and Shiitake (*Lentinula edodes*) extracts. *Ann Transl Med*; 2(2): 14.
- [74] Kurashige S, et al. 1997. Effects of *Lentinus edodes*, *Grifola frondosa* and *Pleurotus ostreatus* administration on cancer outbreak, and activities of macrophages and lymphocytes in mice treated with a carcinogen, N-butyl-N-butanolnitrosoamine. *Immunopharmacol Immunotoxicol*; 19(2): 175–83.
- [75] Sarangi I, et al. 2006. Anti-tumor and immunomodulating effects of *Pleurotus ostreatus* mycelia-derived proteoglycans. *Int Immunopharmacol*; 6(8): 1287–97.
- [76] El-Deeb NM, et al. 2019. Modulation of NKG2D, KIR2DL and cytokine production by *Pleurotus ostreatus* glucan enhances natural killer cell cytotoxicity toward cancer cells. *Front Cell Dev Biol*; 7: 165.
- [77] Gao Y, et al. 2003. Effects of Ganopoly® (a *Ganoderma lucidum* polysaccharide extract) on the immune functions in advanced-stage cancer patients. *Immunol Invest*; 32(3): 201–15.
- [78] Wang G, et al. 2007. Enhancement of IL-2 and IFN- γ expression and NK cells activity involved in the anti-tumor effect of ganoderic acid Me *in vivo*. *Int Immunopharmacol*; 7(6): 864–70.
- [79] Wang PY, et al. 2012. Antitumor and immunomodulatory effects of polysaccharides from broken-spore of *Ganoderma lucidum*. *Front Pharmacol*; 3: 135.
- [80] Chang CJ, et al. 2014. *Ganoderma lucidum* stimulates NK cell cytotoxicity by inducing NKG2D/NCR activation and secretion of perforin and granulysin. *Innate Immun*; 20(3): 301–11.
- [81] Wu YS, et al. 2016. *Ganoderma lucidum* beta 1,3/1,6 glucan as an immunomodulator in inflammation induced by a high-cholesterol diet. *BMC Complement Altern Med*; 16(1): 500.
- [82] Hattori K, et al. 2023. Immunostimulatory effects of a subcritical water extract of *Ganoderma*. *Biomed Rep*; 18(1): 1.
- [83] Arinagi S, et al. 1992. Enhanced induction of lymphokine-activated killer activity after lentinan administration in patients with gastric carcinoma. *Int J Immunopharmacol*; 14(4): 535–9.
- [84] Shin MS, et al. 2019. The effects of AHCC®, a standardized extract of cultured *Lentinula edodes* mycelia, on natural killer and T cells in health and disease: reviews on human and animal studies. *J Immunol Res*; 2019: 3758576.
- [85] Chen S, et al. 2020. Comparison of immunomodulatory effects of three polysaccharide fractions from *Lentinula edodes* water extracts. *J Funct Foods*; 66(1): 103791.